Rimonabant

**peump** · 05-18-2006, 12:52 PM

Rimonabant or SR141716A is an anorectic anti-obesity drug.

any personal experience with RIMONABANT?

i can copy and paste a couple articles if one so desires.

It has been tested on overweight or obese subjects.
I am wondering if anyone here, that would be considered less than obese,
has tried it.

dose?
duration?
effects? (positive & negative)
and would you do it again?

thanks............peump

**HORSE~** · 05-18-2006, 01:09 PM

I dont know anything about it but love to learn.

I so desire.

If you dont mind thank's.

**peump** · 05-18-2006, 02:23 PM

http://www.drugdevelopment-technolog...ts/rimonabant/

i have to paste the next one there would be moral implications involved if i gave a link.

(copy and pasted)
Rimonabant or SR141716A is an anorectic anti-obesity drug. Rimonabant might also be effective as an anti-addictive drug in the treatment of alcoholism as well as nicotine and stimulant addiction. Rimonabant is a CB1 cannabinoid receptor antagonist. Animal studies suggest that cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidemia. The multinational Rimonabant In Obesity (RIO)-Europe study evaluated the effect of rimonabant, a selective CB1 blocker, on weight and cardiovascular risk factors in overweight or obese patients.

In the RIO-Europe study, 1,507 patients with body mass index (BMI) of at least 30 kg/m2 or BMI more than 27 kg/m2 with treated or untreated dyslipidemia, hypertension, or both were randomized to receive double-blind treatment with placebo, 5 mg of rimonabant, or 20 mg of rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit). The main outcome measure was weight change from baseline after one year of treatment based on intent-to-treat analysis.

At one year, weight loss was greater in patients receiving rimonabant, 5 mg (mean, -3.4 ± 5.7 kg; P = .002 vs placebo) and 20 mg (-6.6 ± 7.2 kg; P < .001 vs placebo) compared with placebo (-1.8 ± 6.4 kg). Weight loss in the rimonabant groups was sustained for around 36 to 40 weeks.

Compared with the placebo group, more patients in the group receiving rimonabant, 20 mg, achieved weight loss of 5% or more (67% of patients; P < .001) and 10% or more (39% of patients; P < .001). This group also had significantly greater improvements than placebo in waist circumference (average reduction, 4 cm), high-density lipoprotein (HDL) cholesterol and triglyceride levels, insulin resistance, and prevalence of the metabolic syndrome.

The effects of rimonabant, 5 mg, were not as marked. Overall, rimonabant was well-tolerated, and adverse effects were mild and transient. In all treatment groups, the most common adverse events leading to study discontinuation were depressed mood disorders. Compared with the other groups, withdrawals for nausea, vomiting, diarrhea, headache, dizziness, and anxiety were more frequent in the 20-mg rimonabant group.

**peump** · 05-20-2006, 01:07 PM

bump

**peump** · 05-22-2006, 08:48 PM

.....

**peump** · 05-22-2006, 08:49 PM

bump one more time

**HORSE~** · 05-22-2006, 08:56 PM

Thanks for the info.

If you want ill help keep this bumped till we find some one that's used it.

Id like to know to.

***BajanBastard*** · 06-30-2006, 08:36 PM

Bump

**cj1capp** · 08-14-2006, 02:05 PM

Originally Posted by peump

http://www.drugdevelopment-technolog...ts/rimonabant/

i have to paste the next one there would be moral implications involved if i gave a link.

(copy and pasted)
Rimonabant or SR141716A is an anorectic anti-obesity drug. Rimonabant might also be effective as an anti-addictive drug in the treatment of alcoholism as well as nicotine and stimulant addiction. Rimonabant is a CB1 cannabinoid receptor antagonist. Animal studies suggest that cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidemia. The multinational Rimonabant In Obesity (RIO)-Europe study evaluated the effect of rimonabant, a selective CB1 blocker, on weight and cardiovascular risk factors in overweight or obese patients.

In the RIO-Europe study, 1,507 patients with body mass index (BMI) of at least 30 kg/m2 or BMI more than 27 kg/m2 with treated or untreated dyslipidemia, hypertension, or both were randomized to receive double-blind treatment with placebo, 5 mg of rimonabant, or 20 mg of rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit). The main outcome measure was weight change from baseline after one year of treatment based on intent-to-treat analysis.

At one year, weight loss was greater in patients receiving rimonabant, 5 mg (mean, -3.4 ± 5.7 kg; P = .002 vs placebo) and 20 mg (-6.6 ± 7.2 kg; P < .001 vs placebo) compared with placebo (-1.8 ± 6.4 kg). Weight loss in the rimonabant groups was sustained for around 36 to 40 weeks.

Compared with the placebo group, more patients in the group receiving rimonabant, 20 mg, achieved weight loss of 5% or more (67% of patients; P < .001) and 10% or more (39% of patients; P < .001). This group also had significantly greater improvements than placebo in waist circumference (average reduction, 4 cm), high-density lipoprotein (HDL) cholesterol and triglyceride levels, insulin resistance, and prevalence of the metabolic syndrome.

The effects of rimonabant, 5 mg, were not as marked. Overall, rimonabant was well-tolerated, and adverse effects were mild and transient. In all treatment groups, the most common adverse events leading to study discontinuation were depressed mood disorders. Compared with the other groups, withdrawals for nausea, vomiting, diarrhea, headache, dizziness, and anxiety were more frequent in the 20-mg rimonabant group.

any new info on this